NCT01326702 · OUTCOME

Maximum Tolerated Dose of Veliparib When Combined With Bendamustine Hydrochloride

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors · Source last updated 2019-12-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: mg
Interval / dispersion: Not reported
Time frame: 28 days

What was measured

Maximum Tolerated Dose (MTD) reflects the highest dose of Veliparib when combined with Bendamustine Hydrochloride that did not cause a DLT. The maximum tolerated dose (MTD) was defined as the highest dose level at which 33% of patients experienced DLT.

Analysis population: The MTD was established at Dose Level 6 Veliparib 300mg PO BID plus Bendamustine 90 mg/m2

Groups in this outcome

All Study Participants

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
All Study Participants	43

Reported measurements

Source class 1

Values in mg · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
All Study Participants	300	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
300

denoms

counts
group Id
OG000
value
43
units
Participants

description

groups

description
All Study Participants
id
OG000
title
All Study Participants

param Type

NUMBER

population Description

The MTD was established at Dose Level 6 Veliparib 300mg PO BID plus Bendamustine 90 mg/m2

reporting Status

POSTED

time Frame

28 days

title

Maximum Tolerated Dose of Veliparib When Combined With Bendamustine Hydrochloride

type

PRIMARY

unit Of Measure

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice